NCT06217120View on ClinicalTrials.gov

Reversing Microvascular Dysfunction in Heart Failure With Preserved Ejection Fraction

PHASE2/PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

March 1, 2024

Primary Completion Date

October 1, 2025

Study Completion Date

March 1, 2026

Conditions
Heart Failure With Preserved Ejection FractionMicrovascular Coronary Artery Disease
Interventions
DRUG

Colchicine

Colchicine 0.5 mg daily

DRUG

Placebo

Placebo once daily

Trial Locations (1)

H1T1C8

Montreal Heart Institute, Montreal

All Listed Sponsors
lead

Montreal Heart Institute

OTHER

NCT06217120 - Reversing Microvascular Dysfunction in Heart Failure With Preserved Ejection Fraction | Biotech Hunter | Biotech Hunter